AI assistant
SELLAS Life Sciences Group, Inc. — Director's Dealing 2017
Jul 6, 2017
33651_dirs_2017-07-06_1b5b29be-c756-48d4-a4a0-e745787ffaef.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2017-06-28
Reporting Person: Chin Richard (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-07-06 | Common Stock | A | 8104 | $0.59 | Acquired | 18631 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-08 | Stock Option (right to buy) | $0.55 | A | 5000 | Acquired | 2027-06-08 | Common Stock (5000) | Direct |
Footnotes
F1: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter.
F2: Represents the closing stock price of the Company's stock on the first trading day of the quarter.
F3: Granted pursuant to the Issuer's 2016 Incentive Plan.
F4: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018.